Seattle Genetics has entered into a collaboration agreement with Pfizer, under which Pfizer will pay $8 million upfront for rights to use Seattle Genetics’ antibody-drug conjugate (ADC) technology with antibodies to a single oncology target. ADCs are monoclonal antibodies that selectively deliver potent anti-cancer agents to tumor cells. “This collaboration reflects the increasing value of our ADC technology and strong interest in its potential among leaders in the drug development community...